Benefit
  • Enhanced drug stability
  • Superior pacifying efficiency.

  • Scalable and versatile platform.

     

Technology Description

Researchers at the University of Iowa have developed a novel approach to improving the stability of oral solid dosage forms through the use of engineered calcium carbonate (CaCO₃) particles. By precisely controlling synthesis conditions and incorporating additives, this technology enables the formation of particles with tailored morphology and size, including spherical and hollow structures that enhance light‑scattering performance.

This innovation addresses a critical challenge in pharmaceutical formulation: protecting light‑sensitive drugs from photodegradation. Compared to conventional opacifiers, the engineered CaCO₃ particles offer improved opacity and optical performance, making them a promising solution for use in tablet coatings and capsule shells. This approach provides a scalable and adaptable platform for enhancing drug stability across a wide range of formulations.

UIRF Case No. 2025-089

 

Stage of Development

Validated at the laboratory scale. 

 

IP Status: Patent Pending: Patent pending
 
Lead Researcher(s)
  • Tze Ning Hiew, Assistant Professor of Pharmaceutical Sciences and Experimental Therapeutics.
     
To learn more about this technology, please contact Hozhabr Mozafari.